Mutational Signature-Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High-Grade Ovarian Cancer.
Summary
This study aimed to develop a mutational signature-based biomarker (MSBM) to define homologous recombination deficiency (HRD) in advanced ovarian cancer, overcoming limitations of genomic scar-based assays. The MSBM integrates tumor-BRCA mutation status, Mutational Signature 3 similarity score, and the absence of CCNE1 amplification, derived from whole-exome sequencing. A phase II trial (MSBM-OL) validated this biomarker and evaluated the efficacy of olaparib maintenance monotherapy in HRD-positive patients. The study demonstrated that olaparib significantly extended progression-free survival (22.3 months) compared to a predefined 9-month threshold, confirming its clinical benefit as first-line maintenance therapy.
Analysis
🔴 CLINIQUE: This phase II trial (MSBM-OL) demonstrates a significant clinical benefit of olaparib as first-line maintenance monotherapy for patients with advanced high-grade ovarian cancer who are HRD-positive by MSBM and have responded to platinum-doublet chemotherapy. The median progression-free survival of 22.3 months in the olaparib arm significantly exceeded the predefined 9-month threshold (p < 0.001), suggesting a major clinical impact. The MSBM biomarker is predictive of response to olaparib. Grade ≥ 3 adverse events were manageable (anemia 25.5%, neutropenia 12.8%). These results could justify phase III trials and potentially change clinical practice for selecting patients eligible for olaparib within 1-3 years. 🟢 BIOMOL: The development of MSBM represents a significant advance in HRD assessment, overcoming the limitations of genomic scar-based assays. This novel biomarker integrates three whole-exome sequencing (WES)-derived features: tumor-BRCA mutation status, a Mutational Signature 3 similarity score, and the absence of CCNE1 amplification. Using WES for HRD evaluation offers a robust and comprehensive method. The 81% concordance with the myChoice CDx test and correlation with genomic instability scores (R = 0.63) validate the analytical approach of MSBM. If validated on a larger scale, this test could be integrated into molecular diagnostic platforms to guide therapeutic decisions. 🔵 BIOINFO: The MSBM is an innovative algorithm that integrates whole-exome sequencing-derived features to assess HRD without relying on genomic scars. Its architecture combines tumor-BRCA mutation status, Mutational Signature 3, and CCNE1 amplification status. The study showed that MSBM enables robust HRD evaluation, with 99.5% patient evaluability. While explicit details on algorithmic implementation (open-source code, pre-trained models) are not mentioned, MSBM's ability to identify a large subset of HRD-positive patients (72.4%) suggests potential for improved patient selection. Its clinical deployment could streamline workflows by providing comprehensive HRD assessment from WES data, thereby facilitating targeted treatment decisions.